Evidence map›Paper›PMID 39031992›Full record

ArticleESC heart failure2024

IL-17 is associated with disease severity and targetable inflammatory processes in heart failure.

Lukas Baumhove, Bart J van Essen, Martin M Dokter, Sietske N Zijlstra, Frederik E Deiman, Jon D Laman, Chim C Lang, Gwenny M P J Verstappen, Dirk J van Veldhuisen, Peter van der Meer and 2 more

Abstract read
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Gut microbiota's role in heart failure.Heart failure reviews · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lukas BaumhoveDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Bart J van EssenDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Martin M DokterDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Sietske N ZijlstraDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Frederik E DeimanDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Jon D LamanDepartment of Pathology & Medical Biology, University Medical Center Groningen, Groningen, The Netherlands.
Chim C LangDivision of Molecular and Clinical Medicine, School of Medicine, Ninewells Hospital & Medical School, University of Dundee, Dundee, UK.
Gwenny M P J VerstappenDepartment of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Dirk J van VeldhuisenDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Peter van der MeerDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Nils BomerDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Adriaan A VoorsDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.

Funding

European CommissionFP7-242209-BIOSTAT-CHF; EudraCT 2010-020808-29
6 · The paper itself

Abstract

aimsHeart failure (HF) is recognized as an inflammatory disease in which cytokines play an important role. In animal HF models, interleukin-17A (IL-17) has been linked to deterioration of cardiac function and fibrosis, whereas knock-out of IL-17 showed beneficial cardiac effects. However, there is limited evidence of IL-17 involvement in patients with HF. This study aims to investigate the clinical characteristics, outcomes, and pathophysiological processes associated with circulating IL-17 concentrations in patients with HF. METHODS AND

resultsIL-17 was measured by ELISA in 2082 patients diagnosed with HF along with 363 circulating proteins using proximity extension assay technology for differential expression and pathway analysis. Data were validated in an independent cohort of 1737 patients with HF. Patients with elevated IL-17 concentrations had more severe HF, as reflected by more frequent current or previous hospitalizations for HF, higher New York Heart Association functional class (NYHA) and higher levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP). High IL-17 concentrations were independently associated with an increased risk of hospitalization for HF and mortality. In both cohorts, the most strongly up-regulated proteins in patients with high IL-17 were fibroblast growth factor 21 (FGF-21), interleukin-6 (IL-6), C-X-C motif chemokine ligand 13 (CXCL13), tumour necrosis factor receptor superfamily member 6B (TNFRSF6B) and interleukin-1 receptor antagonist (IL-1RA). Pathway over-representation analysis showed increased activity of pathways related to lymphocyte-mediated immunity, leukocyte activation and regulation of the immune response.

conclusionsIn patients with HF, elevated IL-17 concentrations indicate more severe HF and increased activity of inflammatory processes known to be involved in the pathophysiology of HF. IL-17 might hold potential for identifying and targeting inflammation in HF.

Indexed as

BiomarkersHeart FailureInflammationInterleukin-17Severity of Illness IndexAgedEnzyme-Linked Immunosorbent AssayFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisBiomarkersInterleukin-17cytokinesheart failureinflammation

Identifiers

PMID39031992
PMCPMC11631355

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.